Pharmaron (03759) received a total of 26.38 million shares released from pledge by its actual controller on May 31.
Pharmaron (03759) announced recently that it has received letters from the company's actual controllers, Lou Xiaoqiang and Zhengbei, notifying of...
Pharmaron (300759.SZ) has repurchased a total of 6.8387 million shares at a cost of 150 million yuan.
Pharmaron (300759.SZ) announced that as of May 31, 2024, it repurchased 6.8387 million shares in the centralized bidding trading method, accounting for 0.38% of the company's current total share capital, with a total transaction amount of 150 million yuan (excluding transaction fees).
Intraday Overview | The three major indices fluctuated, and Evergrande Auto resumed trading and rose more than 78%
The pharmaceutical outsourcing concept declined across the board. Pharmaceutical Biotech fell by more than 6%, Kanglong Chemical fell by more than 4%; China Mobile Games rose more than 23%, and its two new games will be launched soon; Lenovo Group has risen more than 7%, and the market share of Daimo AI PC will continue to rise.
The Hong Kong stock CXO concept fluctuated and declined, and Pharmaceutical Biotech fell more than 7%
Gelonghui, May 27 | Pharmaceutical Biotech fell more than 7%, while Kanglong Chemical, Pharmaceutical Kangde, Gloria Ying, Zhaoyan Pharmaceutical, and Tiger Pharmaceuticals followed suit.
Kanglong Chemical (03759.HK): Yongxin Kangjun Fund has completed the industrial and commercial registration procedures
Gelonghui, May 24, 丨 Kanglong Chemical (03759.HK) announced that on December 22, 2023, Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. (hereinafter referred to as the “Company”) held the 5th meeting of the 3rd board of directors and the 5th meeting of the 3rd board of supervisors to review and pass the “Proposal on Participation in Private Equity Investment Funds and Related Transactions”, agreeing that the company, as a limited partner, will use its own capital to commit RMB 280 million, and the related party Kangjun Investment Management (Beijing) Co., Ltd. as a general partner and associated party, Beijing Xinyuan Kang Management consulting partnership (yes
May 21 repurchase collection | Tencent Holdings, HSBC Holdings, etc. have repurchased, of which Tencent Holdings spent HK$1.03 billion
According to documents disclosed by the Hong Kong Stock Exchange on May 22, $Tencent Holdings (00700.HK) $ and $HSBC Holdings (00005.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 2.61 million common shares on May 21, involving an amount of HK$1,003 billion. The repurchase price per share ranged from HK$393.4 to HK$379.8. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 6.2 million shares, accounting for 0.066% of the number of shares issued when the ordinary resolution was passed.
Pharmaron Beijing Reports Share Repurchase
Kanglong Chemical (03759.HK) spent 16.616 million yuan to buy back 762,200 A shares on May 21
Kanglong Chemical (03759.HK) announced that it spent 16.616 million yuan to buy back 762,200 A shares on May 21.
Kanglong Chemical (300759): Strengthening cash flow from the sale of overseas equity participation
Key Investment Companies sell shares in overseas participating companies, and we expect to make a positive contribution to the profit side in 2024. Event: Sale of PROTEOLOGIX Shares, Cash Flow Enhancement May 17 Company Announcement: PROTEO
Improve quality and expand! The National Health Insurance Administration issued a new collection document “There is a lot of information” to set the tone for new trends in collection and procurement
① Yesterday evening, the National Health Insurance Administration issued the “Notice on Strengthening Regional Collaboration to Improve Quality and Expand Centralized Pharmaceutical Procurement in 2024", which provides further instructions on “improving quality and expansion” of collection; ② Many interprovincial alliance procurement will soon be upgraded to national joint procurement, which has attracted strong attention from the industry. In particular, the provinces covered by the Sanming Alliance and Henan Alternative Medicine Alliance will be further expanded, and proprietary Chinese medicine and Chinese medicine tablet companies need to prepare early.
Intraday Overview | The three major indices fell sharply, and the science index fell more than 3%; auto stocks and pharmaceutical outsourcing concept stocks weakened; after ideal car performance, it plummeted nearly 20%
The Hang Seng Index fell 2.2%, and the Tech Net Index fell by 3.41%; most of the shares fell by more than 7%, JD Health and NIO by more than 6%, Bilibili by more than 5%, and Tencent, Ali, Baidu, and NetEase by more than 3%.
Kanglong Chemical (300759): Selling shares in overseas participating companies for about US$102.1 million is expected to increase net profit for 24 years
On May 16, Johnson & Johnson announced that it would acquire Proteologix with an all-cash payment of US$850 million, while possibly making additional milestone payments in the future. Kang Longxiang
On May 20, Kanglong Chemical announced that it has reached a comprehensive strategic cooperation with AstraZeneca China on integrated R&D and commercial production services throughout the entire process of drug discovery, pre-clinical and clinical develop
On May 20, Kanglong Chemical announced that it has reached a comprehensive strategic cooperation with AstraZeneca China on integrated R&D and commercial production services throughout the entire process of drug discovery, pre-clinical and clinical development, and investment in innovative drug research and development, including small molecules, macromolecules, and cell and gene therapy drugs. At the same time, Kanglong Chemical plans to invest an additional 91 million yuan in the Wuxi AstraZeneca CICC Venture Capital Fund in the near future. The two sides will give full play to the resources and experience advantages of the industry-leading healthcare sector and the entire global industry chain to help innovative medical enterprises grow.
Pharmaron Beijing Unit to Sell Proteologix Stake to Johnson & Johnson
A unit of Pharmaron Beijing (HKG:3759, SHE:300759) is selling its 10.2% stake in Proteologix to Johnson & Johnson, a May 17 filing on the Hong Kong bourse said. Johnson & Johnson is merging Proteologi
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
May 17 Repurchase Collection | Tencent Holdings, HSBC Holdings, etc. repurchased, of which Tencent Holdings spent HK$415 million
According to HKEx disclosure documents on May 20, $Tencent Holdings (00700.HK) $ and $HSBC Holdings (00005.HK) $ repurchased shares. ① $Tencent Holdings (00700.HK) $ repurchased 1.05 million common shares on May 17, involving an amount of HK$415 million. The repurchase price per share ranged from HK$395 to HK$394.4. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 1.05 million shares, accounting for 0.011% of the number of shares issued when the ordinary resolution was passed. ② $HSBC Holdings (00005
Kanglong Chemical (03759) plans to sell its shares in Proteologix Investments and is expected to receive an initial payment of approximately US$86.821 million
Kanglong Chemical (03759) issued an announcement regarding the sale of the Group's interest in PROTEOLOGIX, INC.
Kanglong Chemical (03759) spent 128 million yuan to buy back 5.826,500 A shares on May 17
Kanglong Chemical (03759) announced that on May 17, 2024, the company spent 128 million yuan to buy back...
Kanglong Chemical (03759) will distribute the 2023 final dividend of 2 yuan for every 10 shares on July 26
Kanglong Chemical (03759) announced that the company will distribute the end of 2023 on July 26, 2024...
NOTICE OF THE ANNUAL GENERAL MEETING OF 2023
No Data